



Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Santos, VV;Stark, R;Rial, D;Silva, HB;Bayliss, JA;Lemus, MB;Davies, JS;Cunha, RA;Prediger, RD;Andrews, ZB

Title:

Acyl ghrelin improves cognition, synaptic plasticity deficits and neuroinflammation following amyloid β ($A\beta$ 1-40) administration in mice

Date:

2017-05-01

Citation:

Santos, V. V., Stark, R., Rial, D., Silva, H. B., Bayliss, J. A., Lemus, M. B., Davies, J. S., Cunha, R. A., Prediger, R. D. & Andrews, Z. B. (2017). Acyl ghrelin improves cognition, synaptic plasticity deficits and neuroinflammation following amyloid β ($A\beta$ 1-40) administration in mice. *Journal of Neuroendocrinology*, 29 (5), <https://doi.org/10.1111/jne.12476>.

Persistent Link:

<https://hdl.handle.net/11343/292846>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

PROFESSOR JEFFREY S DAVIES (Orcid ID : 0000-0002-4234-0033)

DR ZANE B. ANDREWS (Orcid ID : 0000-0002-9097-7944)

Article type : Original Article

Acyl ghrelin improves cognition, synaptic plasticity deficits and neuroinflammation following amyloid beta (A β 1-40) administration in mice

Vanessa V Santos¹, Romana Stark¹, Daniel Rial^{3,4}, Henrique B. Silva⁴, Jacqueline A Bayliss¹, Moyra B Lemus¹, Jeffrey S. Davies², Rodrigo A. Cunha^{4,5}, Rui Daniel Prediger³, Zane B. Andrews¹.

1. Monash Biomedicine Discovery Institute and Department of Physiology, Monash University, Clayton, Australia

2. Molecular Neurobiology, Institute of Life Science, Swansea University, Swansea, SA28PP, UK

3. Department of Pharmacology, Center of Biological Sciences, Universidade Federal de Santa Catarina, UFSC, Florianópolis, 88049-900, SC, Brazil;

4. CNC - Center for Neuroscience and Cell Biology, University of Coimbra, 3004-517 Coimbra, Portugal.

5. Faculty of Medicine, University of Coimbra, 3004-504 Coimbra, Portugal.

Corresponding author: A/Prof Z. B. Andrews: Email: Zane.Andrews@monash.edu Tel: +61 3 9905 8165

Key words: Acyl ghrelin, Alzheimer's disease, amyloid beta, Y-maze, novel object recognition, olfactory discrimination, ghrelin knockout.

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/jne.12476

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

Abstract word count: 248

Article word count: ~5600

Disclosure Statement: The Authors have nothing to disclose

Acknowledgements This work was supported by grants and fellowships from the Australian National Health and Medical Research Council to Z.B.A (546131, 1084344) and Australian Research Council to Z.B.A (FT100100966) and Santa Casa da Misericórdia and QREN to R.A.C. V.V.S was supported by the Brazilian Funding Agency CNPq “Science without Borders”. RDP is supported by a research fellowship from CNPq-Brazil.

Conflict of Interest The authors declare that there are no conflicts of interest.

ABSTRACT

Ghrelin is a metabolic hormone that has neuroprotective actions in a number of neurological conditions including Parkinson’s disease (PD), stroke and traumatic brain injury. Acyl ghrelin treatment *in vivo* and *in vitro* also shows protective capacity in Alzheimer’s disease (AD). In this study, we used ghrelin knockout (KO) and their wildtype (WT) littermates to test whether or not endogenous ghrelin is protective in a mouse model of AD, in which human amyloid beta peptide ($A\beta_{1-40}$) was injected into the lateral ventricles (icv). Recognition memory, using the novel object recognition task, was significantly impaired in ghrelin KO mice and after icv $A\beta_{1-40}$ treatment. These deficits could be prevented by acyl ghrelin injections for 7 days. Spatial orientation, as assessed by the Y-maze task, was also significantly impaired in ghrelin KO mice and after icv $A\beta_{1-40}$ treatment. These deficits could be prevented by acyl ghrelin injections for 7 days. Ghrelin KO mice had deficits in olfactory discrimination, however, neither icv $A\beta_{1-40}$ treatment nor acyl ghrelin injections affected olfactory discrimination. We used stereology to show that ghrelin KO and $A\beta_{1-40}$ increased the total number of glial fibrillary acidic protein expressing astrocytes and ionized calcium-binding adapter expressing microglial in the rostral hippocampus. Finally, $A\beta_{1-40}$ blocked long-term potentiation induced by high frequency stimulation and this effect could be acutely blocked with co-administration of acyl ghrelin. Collectively, our studies highlight ghrelin deletion affects memory performance and that acyl ghrelin treatment may delay the onset of early events of AD. This supports the idea that acyl ghrelin treatment may be therapeutically beneficial to restrict disease progression in AD.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

INTRODUCTION

The stomach hormone ghrelin is best known for its effects on metabolism, including food intake, blood glucose regulation and adiposity (1, 2). However, additional studies show that ghrelin plays an important role in non-metabolic functions, including learning, memory, stress, anxiety, fear, pain, vascular function and neuroprotection. In the plasma, ghrelin exists in an acylated and des-acylated form with des-acyl ghrelin being the most abundant. Acyl ghrelin, but not des-acyl ghrelin, activates the only known ghrelin receptor (GHSR; Growth Hormone Secretagogue Receptor), which is located in several regions throughout the brain, including the hypothalamus, substantia nigra, olfactory bulb, brain stem and hippocampus (3).

In terms of neuroprotection, numerous studies have identified that ghrelin prevents degeneration in animal models of Parkinson's disease (PD). Recently, we demonstrated that ghrelin mediates the neuroprotective benefit of calorie restriction in PD by controlling AMPK in substantia nigra dopamine neurons (4). Of course, calorie restriction will impact upon numerous physiological systems and recent evidence shows that ghrelin may link calorie restriction with increased neurogenesis (5), blood glucose production (6, 7) and mood (8). Collectively these studies show that ghrelin is a signal of energy deficit to the brain and that the effective actions of ghrelin are greater in states of negative energy balance (2, 9).

Alzheimer's disease (AD) is another neurological disease that may benefit from forms of calorie restriction (10, 11). If ghrelin was a common neuroendocrine feedback signal linking metabolic state to neuroprotection, then it is expected that ghrelin would also promote neuronal resilience in different models of AD. Indeed, human males with mild stage AD show significantly lower plasma ghrelin than aged matched controls, although no difference in females was observed (12). A single nucleotide polymorphism (Leu90Gln) in the ghrelin gene was associated with age of AD onset in a Japanese population (13). Moreover, a number of *in vivo* and *in vitro* studies show that ghrelin or GHSR agonists improve cognition and neuronal function in models of AD. For example, peripheral ghrelin improved T-maze footshock avoidance in a U-shaped dose response curve in young and old SAMP8 KO mice (14), which exhibit an age-related increase in amyloid beta ($A\beta$), the peptide involved in brain amyloid plaques in AD and impaired learning and memory (14). Moon *et al.* reported that peripheral ghrelin injections rescue memory deficits, prevent microgliosis and neuronal or synaptic degeneration in an AD mouse model induced by intrahippocampal injections of $A\beta$

1 (15). These results have been confirmed with a central infusion of acyl ghrelin, which
2 improved memory function, hippocampal AMPK activation and decreased A β deposition (16).
3 In cultured hippocampal neurons, ghrelin ameliorated A β -induced cell death by preventing
4 mitochondrial dysfunction (17).
5 In the 5XFAD AD mouse model, hippocampal neuroblast number is significantly reduced
6 compared to WT controls and peripheral ghrelin injections restore this neurogenic capacity;
7 whether or not this produced any functional recovery was not examined (18). However, these
8 results are consistent with acyl-ghrelin-induced adult hippocampal neurogenesis via
9 hippocampal GHSR activation in healthy lean mice (5) and rats (19). Long-term treatment
10 with the GHSR agonist, LY444711, improves performance in a water maze and reduces
11 microglial activation and amyloid beta (A β) (20). However, recent work from the same group
12 using the same agonist failed to replicate this finding (21).
13 While the studies above demonstrate that administration ghrelin improves outcomes in
14 mouse or rat models of AD, or *in vitro*, there is no evidence to show that endogenous ghrelin
15 provides a protective effect that prevents or restricts cognitive loss in models of AD.
16 Therefore, in this study we have used ghrelin wild type (WT) and ghrelin knockout (KO) mice
17 in order to determine whether or not endogenous ghrelin prevents cognitive decline after
18 intracerebroventricular (icv) A β administration. We further examined the protective actions of
19 acyl ghrelin administration in ghrelin WT and KO mice and explored the possible impact of
20 ghrelin and A β in two processes known to critically impact on memory performance, namely
21 neuroinflammation and synaptic plasticity.

22 **METHODS**

23 Animals

24 All experiments were conducted in compliance with the guidelines of the Animal Ethics
25 Committees of the Monash University and of the Center for Neuroscience and Cell Biology of
26 the University of Coimbra. Mice were kept at standard laboratory conditions with free access
27 to food and water at 23 °C in a 12-hour light/dark cycle unless otherwise stated. Male ghrelin
28 KO on a C57/Bl6 background were obtained from Regeneron Pharmaceuticals (Tarrytown,
29 NY) and bred at the Monash Animal Services. All mice were group-housed to prevent
30 isolation stress. All mice were 10-12 weeks of age at time of experimentation.

31

32 Treatment

33 Ghrelin KO mice that produce neither acylated nor des-acylated ghrelin (22, 23) were used to
34 examine whether endogenous ghrelin prevents cognitive decline and neuroinflammation after
35 icv injection of human amyloid-beta peptide 1-40 (A β ₁₋₄₀) (cat # A1075, Sigma, USA). A β ₁₋₄₀
36 was prepared as a stock solution at 1 mg/ml in sterile phosphate buffered saline (PBS, 0.1

1 M; pH 7.4) and A β ₁₋₄₀ protein fragments were aggregated for 4 days at 37°C, as previously
2 described (24). Mice were anaesthetised with isoflurane/oxygen mixture and mounted in a
3 stereotaxic apparatus (Stoelting Co, Wood Dale, IL, USA). Mice were injected icv with 400
4 pmol of A β ₁₋₄₀ or PBS (1 μ l injection volume) using the following coordinates; bregma
5 anterior/posterior 0.2 mm, medial/lateral 0.8 mm and dorsal/ventral 2.1 mm according to a
6 mouse brain atlas as a guide (Franklin and Paxinos). Acyl-ghrelin (0.3 mg/kg) was injected ip
7 daily for 7 days after A β ₁₋₄₀ injection at approximately 9 am each morning. Food was
8 removed immediately after ip injection for 6 hours after the injections, as performed
9 previously to prevent immediate food intake (4, 25, 26), which alters metabolic feedback and
10 negates ghrelin signaling properties.

11

12 Behavioural testing

13 Behaviour testing occurred between days 6-17 since the start of ghrelin injections and mice
14 were tested for novel object recognition, Y-maze performance and olfactory discrimination
15 according to the timeline established in figure 1. All behavioural tests were conducted at least
16 2 days apart to reduce any potential stress associated with behavioural testing. All
17 behavioural testing was conducted between 9 am and 2 pm.

18 All tests were performed in an experimental room with sound isolation and dim light. The
19 animals were carried to the test room for at least 1 hour of acclimation. Behaviour was
20 monitored using a video camera positioned above the apparatuses and the videos were later
21 analyzed by an experienced blinded researcher using video tracking software (CleverSys
22 Inc, Reston, VA, USA).

23 *Novel object recognition (NOR)*: The NOR task exploits a mouse's natural tendency to
24 explore a novel object after previous exposure to two identical objects. At 10-12 weeks of
25 age, mice (n=8) were habituated for 3 periods of 10 minutes each separated with 10 minutes
26 in its home cage to reduce anxiety associated with the novel arena (plastic arena 30 x 30 x
27 50 cm). After habituation, mice were ready for the NOR task, which was conducted using two
28 trials (familiarisation trial [T1] and test trial [T2]) separated by 30 minutes. During T1, mice
29 were allowed to explore for 10 minutes two identical objects (plastic screw-top tubes)
30 secured to the floor using a small amount of Blu Tack in habituated arenas. For T2, one
31 identical object from T1 was replaced with a novel object (small green flask) and mice were
32 allowed to freely explore for 5 minutes. T1 and T2 were recorded using a video camera and
33 analyzed for the time spent interacting with the novel object. All arenas were washed and
34 dried and then sprayed with 80% ethanol prior to experimentation. Novel object exploration
35 was calculated in T2 by $(T_{\text{novel}} \times 100) / (T_{\text{novel}} + T_{\text{identical}})$ with exploration defined as the nose

1 being less than 1 cm from the object when facing the object or actively engaging with the
2 object by sniffing or paw touching. Climbing on the object was not considered exploration.

3 *Modified Y-maze:* The modified Y-maze measures spatial memory, as spatial orientation
4 cues facilitate rodents to explore a novel arm rather than returning to a previously visited
5 arm. We used a Y-shaped grey Perspex maze (30 cm x 10 cm x 16 cm) and each arm could
6 be isolated by blocking entry with a sliding door. Saw dust from a mouse's home cage lined
7 the maze during the trials and extra maze cues on the walls were placed 30-40 cm from the
8 end of the arms to provide spatial orientation cues. Behaviour was tested across two trials,
9 the first of which had one arm of the maze randomly blocked off. Mice were allowed to
10 explore the reduced maze for 10 minutes and then returned to their home cage. The second
11 trial was conducted 30 minutes after the first trial and both arms of the maze were opened.
12 Mice were placed in the start arm and allowed to explore the full maze for 5 minutes. All
13 behaviours were recorded and analyzed using tracking software. Novel arm exploration was
14 record when all 4 feet of each mouse entered the novel arm. The apparatus was cleaned
15 with 80% ethanol between each trial and each animal.

16 *Olfactory discrimination:* The task is based on the fact that mice prefer places with their own
17 odor (familiar compartments) instead of places with unfamiliar odors. In this test, mice have
18 access to 2 adjacent identical chambers separated by an intermediate zone. One chamber
19 contained familiar bedding from its home cage over the last 48 hours (familiar) whereas the
20 other contained fresh bedding (non-familiar). Mice were placed into the intermediate zone
21 and allowed to freely explore each chamber. Rodents are capable of discriminating familiar
22 versus non-familiar chambers since they prefer their odour to no odour at all. The time spent
23 in each chamber was recorded and analyzed. An olfactory discrimination index was
24 generated according to the following $t_{\text{familiar}}/(t_{\text{familiar}} + t_{\text{non-familiar}})$, where t equal time and 0.5
25 equals no preference.

26 27 Immunohistochemistry and stereology

28 We collected every section (30 μm thickness) in sets of 4 through the rostral hippocampus
29 from bregma -0.9 mm to -2.5 mm. Every 4th section was washed in 0.1 M PB and incubated
30 with 1% hydrogen peroxide (H_2O_2) for 15 minutes to prevent endogenous peroxidase activity
31 and blocked for 1 hour with 5% normal horse serum (NHS) in 0.1 M PB with 0.3% Triton. In
32 order to assess neuroinflammation, we quantified astrocytosis by immunostaining for glial
33 fibrillary acidic protein (GFAP; rabbit anti-GFAP antibody from Abcam, USA, Cat no. 7260)
34 and the microglial marker ionized calcium-binding adapter molecule (Iba1; rabbit anti-Iba1
35 antibody from Wako, Japan Cat no. #019-19741) all at 1:1000 in PB 0.1 M with 1% NHS and
36 0.3% Triton. After incubation with the primary antibodies, the sections were washed and
37 incubated with biotin-SP-conjugated goat anti-rabbit IgG (Jackson ImmunoResearch

1 Laboratories, Inc. West Grove, PA, USA) at 1:200 in 0.1 M PB. Sections were then washed
2 and incubated with avidin-biotin complex (ABC, 1:200) for 90 minutes. To visualise
3 immunoreactivity, sections were incubated with a solution containing 1% nickel ammonium
4 sulfate, 1% Diaminobenzidine and 4 μ l of 30% H_2O_2 . Sections were then washed in 0.1 M
5 PB, mounted and coverslipped. The non-specific staining of our antibodies used was
6 confirmed with controls where we omitted the addition of the primary antibody.

7 *Stereology*: We employed a design-based approach to quantify GFAP- and Iba1-positive
8 cells in the rostral hippocampus using the Stereoinvestigator software (MicroBrightField,
9 Williston, VT, USA). We used a Zeiss microscope with a motorised stage coupled with a
10 MicroFibre digital camera to a computer. Cells were counted using the optical fractionator
11 probe on both sides of the brain, controlled by Stereoinvestigator software in randomly
12 positioned grids in a defined region to create a collection of 3 dimensional counting areas.
13 Guard zones were set at 10% of the section thickness to account for damage during the
14 staining procedure and to prevent overcounting. The counting frame width (X) and height (Y)
15 was 40.2 μ m producing a counting frame area (XY) of 1616 μ m². The dissector height (Z)
16 was 20 μ m creating a dissector volume (XYZ) of 32320 μ m³. With this counting frame area
17 we discovered that we needed to sample approximately 150-200 sites throughout the entire
18 rostral hippocampus and count approximately 200-250 labeled cells throughout the rostral
19 hippocampus to obtain a coefficient of error (using the Gundersen method) of 0.1 using a
20 smoothness factor $m=1$. Cells were only counted if they touched the inclusion border or did
21 not touch the exclusion border of the sampling grid.

23 Electrophysiology

24 Electrophysiological recordings were carried out as previously described (27). Briefly, mice
25 (C57Bl/6) were deeply anesthetized under a halothane-saturated atmosphere (Sigma-
26 Aldrich, St Louis, MO, USA) before decapitation. Brains were quickly removed and placed in
27 ice-cold standard artificial cerebrospinal fluid (aCSF) containing (in mM); 124 NaCl, 4.5 KCl,
28 2 $CaCl_2$, 1 $MgCl_2$, 26 $NaHCO_3$, 1.2 NaH_2PO_4 and 10 D-glucose, gassed with 95% O_2 and
29 5% CO_2 . The hippocampi were cut in 400 μ m thick transverse slices using a Mcllwain tissue
30 chopper (Mickle Lab Engineering, Guildford, UK) and kept in oxygenated aCSF at room
31 temperature for at least 60 minutes, before being used. Individual slices were transferred to a
32 recording chamber and superfused with oxygenated aCSF at 30.5 $^{\circ}C$ at a flow rate of 3
33 mL/min. Bipolar stainless steel electrodes were placed on the Shaffer collateral/commissural
34 fibers and test stimuli were delivered via a S44 stimulator (Grass Instruments, West Warwick,
35 RI) with a stimulus isolation unit (PSIU6, Grass Instruments) at a frequency of 0.06 Hz. Glass
36 microelectrodes (1–2 $M\Omega$) filled with 4 M NaCl were used to record field excitatory
37 postsynaptic potentials (fEPSPs) in the stratum radiatum of the CA1 region of hippocampus.

1 Recordings were obtained using an ISO-80 amplifier (World Precision Instruments,
2 Hertfordshire, UK) and digitized using an ADC-42 board (Pico Technologies, Pelham, NY,
3 USA). Averages of 4 consecutive responses were continuously monitored on a personal
4 computer with the LTP 1.0.1 software (28).

5 An input-output curve was first carried out to evaluate the threshold to the maximum
6 response and the working stimulus intensity was adjusted to evoke fEPSPs of half maximal
7 amplitude (50%). Long-term potentiation (LTP) was induced with a protocol of high-frequency
8 stimulation (HFS) with pulses delivered at 100 Hz during 1 second; the fEPSPs were
9 recorded for an additional 60 minutes. The average slope of the fEPSP at baseline was set
10 at 100%, and changes of the fEPSP slope calculated 50-60 minutes after delivery of the HFS
11 train were expressed as percent of change from baseline to estimate the amplitude of LTP.
12 $A\beta_{1-40}$ (200 or 500 nM) and ghrelin (1 nM or 1 μ M) were added through the superfusion
13 system 30 minutes before LTP induction and kept in the superfusate until the end of the
14 experiment. When testing the interaction between ghrelin (1 nM) and $A\beta_{1-40}$ (200 nM) both
15 were added simultaneously to the superfusion system 30 minutes before LTP induction.

16 17 Statistical analysis

18 All data are represented as mean \pm standard error of the mean (SEM). A three-way analysis
19 of variance (ANOVA), or a two-way ANOVA, with Tukey's *post hoc* tests for multiple
20 comparisons were used to determine statistical significance between genotype, peptide and
21 hormone treatment. $p < 0.05$ was considered statistically significant. Data were plotted and
22 analysed using Prism 7.0b for Mac OS X.

23 24 25 **RESULTS**

26 **NOR**

27 The NOR is a highly-validated test for recognition memory and exploits a mouse's natural
28 tendency to explore a novel object after previous exposure to two identical objects. To
29 examine the effect of icv $A\beta_{1-40}$ on recognition memory, we measured NOR in ghrelin WT or
30 KO mice injected with aCSF or $A\beta_{1-40}$ icv and then injected daily ip with either saline or acyl
31 ghrelin (Fig 2). A three-way ANOVA revealed a main effect of hormone treatment ($F=12.33$;
32 $p=0.001$), genotype ($F=22.03$; $p < 0.0001$) and peptide treatment ($F=9.449$; $p=0.0035$). There
33 was a significant interaction between hormone treatment and genotype ($F=4.05$; $p=0.0498$)
34 and a significant interaction between hormone treatment x genotype x peptide treatment
35 ($F=4.751$; $p=0.0342$) (Fig 2).

1 NOR was significantly reduced in ghrelin WT mice injected icv with $A\beta_{1-40}$ and saline (ip),
2 compared to ghrelin WT mice injected with icv aCSF and saline (ip) (Fig 2), indicating that
3 $A\beta_{1-40}$ reduces recognition memory. Daily acyl ghrelin injections for 7 days significantly
4 improved NOR in ghrelin WT mice treated with icv $A\beta_{1-40}$ and ghrelin KO mice treated with
5 either aCSF or icv $A\beta_{1-40}$ (main effect of hormone treatment), although it did not improve
6 NOR in WT mice treated with icv aCSF (Fig 2). These results indicate acyl ghrelin can
7 overcome the deficit in NOR caused by $A\beta_{1-40}$, but it does not potentiate NOR in ghrelin WT
8 mice without $A\beta_{1-40}$ -induced pathology (i.e. treated icv with aCSF). Ghrelin KO mice treated
9 with either icv aCSF or $A\beta_{1-40}$ and daily ip saline injections could not discriminate between
10 novel and familiar objects based on 50% exploration time of both objects (Fig 2). However,
11 daily acyl ghrelin injections for 7 days to ghrelin KO mice resulted in significantly increased
12 recognition memory (NOR) in both ghrelin KO mice treated icv with aCSF or $A\beta_{1-40}$. NOR
13 was significantly reduced in ghrelin KO compared to ghrelin WT mice injected daily with
14 saline, indicating that genotype alone significantly affects NOR (main effect of genotype).
15 $A\beta_{1-40}$ reduced NOR to 50% in both ghrelin WT and KO mice (main effect of peptide
16 treatment), where 50% represents no ability to discriminate between novel and familiar
17 objects. Thus, deletion of ghrelin or $A\beta_{1-40}$ alone is sufficient to reduce recognition memory to
18 chance, which can be overcome with acyl ghrelin treatment. This floor effect means that the
19 combination of ghrelin KO mice and $A\beta_{1-40}$ administration cannot further impair NOR.

20

21 **Modified Y-maze**

22 The modified Y-maze is a highly-validated test for spatial memory, which utilizes spatially
23 orientated visual cues to help rodents explore a previously unexplored novel arm. To
24 examine the effect of icv $A\beta_{1-40}$ on spatial memory, we measured novel arm exploration
25 (seconds) in ghrelin WT or KO mice injected icv with either aCSF or $A\beta_{1-40}$ and then injected
26 daily ip with either saline or acyl ghrelin (Fig 3). A three-way ANOVA revealed a main effect
27 of hormone treatment ($F=15.8$; $p=0.0002$), genotype ($F=16.79$; $p=0.0002$) and peptide
28 treatment ($F=14.66$; $p=0.0004$). There was a significant interaction between hormone
29 treatment and genotype ($F=5.232$; $p=0.0266$), genotype and peptide treatment ($F=13.56$;
30 $p=0.0006$) and a significant interaction between hormone treatment x genotype x peptide
31 treatment ($F=8.404$; $p=0.0056$) (Fig 2).

32 Novel arm exploration was significantly reduced in ghrelin WT mice injected icv with $A\beta_{1-40}$
33 and saline ip, compared to ghrelin WT mice injected icv with aCSF and saline ip (Fig 3),
34 indicating that $A\beta_{1-40}$ impairs spatial memory. Daily acyl ghrelin injections for 7 days
35 significantly improved novel arm exploration in ghrelin WT mice treated icv with $A\beta_{1-40}$ and
36 ghrelin KO mice treated with either aCSF or icv $A\beta_{1-40}$ (main effect of hormone treatment) but

1 not in mice treated icv with aCSF (Fig 3). Similar to results from the NOR tests, these results
2 suggest acyl ghrelin overcomes the deficit in novel arm exploration caused by $A\beta_{1-40}$, but it
3 cannot enhance novel arm exploration in ghrelin WT mice without $A\beta_{1-40}$ -induced pathology.
4 Ghrelin KO mice treated icv with either aCSF or $A\beta_{1-40}$ and injected daily with ip saline could
5 not differentiate between the novel arm and the previously explored arm (Fig 3). However,
6 daily ip acyl ghrelin increased novel arm exploration in both icv aCSF and $A\beta_{1-40}$ treated
7 ghrelin KO mice (Fig 3). Novel arm exploration was reduced in ghrelin KO mice without $A\beta_{1-40}$.
8 $A\beta_{1-40}$ treatment compared to ghrelin WT mice treated icv with $A\beta_{1-40}$ (main effect of genotype;
9 Fig 3). $A\beta_{1-40}$ reduces novel arm exploration in ghrelin WT mice to ghrelin KO mouse levels
10 (main effect of peptide treatment), although $A\beta_{1-40}$ does not further reduce novel arm
11 exploration when compared to ghrelin KO mice treated icv with aCSF (Fig 3C). Thus,
12 deletion of ghrelin or $A\beta_{1-40}$ alone reduces novel arm exploration to a similar degree, which
13 cannot be reduced further in ghrelin KO mice after $A\beta_{1-40}$.

14

15 **Olfactory discrimination**

16 As deficits in olfactory processing are a common feature in early stages of AD (29) and
17 ghrelin regulates olfactory processing in mice and humans (30), we used an olfactory
18 discrimination test to determine whether $A\beta_{1-40}$ affects olfactory discrimination in ghrelin WT
19 and KO mice. We also tested whether exogenous acyl ghrelin could improve olfactory
20 discrimination in ghrelin WT and KO mice. Specifically we chose to examine olfactory
21 behaviour 10 days after the final acyl ghrelin ip injection since olfactory discrimination is
22 reported to require olfactory neurogenesis (31-34) and this time frame influences
23 hippocampal neurogenesis (35). A three-way ANOVA revealed a main effect of genotype
24 ($F=30.91$; $p<0.0001$) and no effects of hormone treatment or peptide treatment were
25 observed. Moreover, no significant interactions were observed. All WT groups of mice could
26 discriminate between chambers paired with familiar and fresh bedding (i.e. discrimination
27 index > 0.5 ; Fig 4). In contrast, ghrelin KO groups of mice could not discriminate between
28 familiar and fresh bedding, as indicated by an index of 0.5, regardless of icv treatment or
29 daily injection of saline or acyl ghrelin (main effect of genotype; Fig 4). These results indicate
30 that ghrelin KO mice exhibit a deficit in olfactory discrimination irrespective of hormone or
31 peptide treatment.

32

33 **Stereological analysis of GFAP and Iba1 in the rostral hippocampus**

34 In order to examine the effect of $A\beta_{1-40}$ on neuroinflammation in ghrelin WT and KO mice, we
35 performed a stereological analysis of GFAP and Iba1 cell number in the rostral hippocampus.
36 Ghrelin KO mice had greater GFAP-positive cells compared to WT mice treated icv with

1 aCSF (Fig 5A). $A\beta_{1-40}$ administration significantly increased GFAP-positive cell number in
2 ghrelin WT mice, whereas there was no further increase in GFAP-positive cell number in
3 ghrelin KO mice treated icv with $A\beta_{1-40}$ compared to ghrelin KO mice treated icv with aCSF
4 (Fig 5A). A similar effect was seen in Iba1 microglial number, although absolute numbers of
5 Iba1-positive cells were lower than GFAP-positive cells. The number of Iba1-positive cells
6 was larger in ghrelin KO mice treated icv with aCSF compared to ghrelin WT mice treated icv
7 with aCSF. Furthermore, $A\beta_{1-40}$ treatment significantly increased Iba1-positive microglia cells
8 in ghrelin WT mice, but not in ghrelin KO mice (Fig 5B). This indicates that ghrelin deletion
9 increases the number of GFAP-positive and Iba1-positive cells in the rostral hippocampus.
10 Likewise, icv treatment with $A\beta_{1-40}$ also increases the number of GFAP-positive Iba1-positive
11 cells in the rostral hippocampus in the presence, but not in the absence, of ghrelin.

12

13 **Hippocampal LTP**

14 The electrophysiological analysis in hippocampal slices revealed that $A\beta_{1-40}$ (200 and 500
15 nM) did not significantly modify basal (i.e. low frequency) synaptic transmission ($P > 0.05$)
16 (data not shown), but decreased LTP amplitude ($P < 0.05$) (Fig 6A and B). Similarly, the
17 administration of a low (1 nM) or a high concentration (1 μ M) of ghrelin did not significantly
18 modify basal synaptic transmission but increased ($P < 0.05$) the amplitude of HFS-induced
19 LTP (Fig 6C and D).

20 The possible interaction between the effects of ghrelin and $A\beta_{1-40}$ on hippocampal LTP was
21 investigated using the lower effective concentration of $A\beta_{1-40}$ (200 nM) and ghrelin (1 nM).
22 We found that the concomitant administration of ghrelin blunted ($P < 0.05$) the depressive
23 effect of $A\beta_{1-40}$ on the amplitude of HFS-induced LTP (Fig 6E and F).

24

25

26

27 **DISCUSSION**

28 Our results indicate 5 key findings; 1) ghrelin KO mice have deficits in spatial, recognition
29 and olfactory memory based on the results from Y-maze, NOR and olfactory discrimination
30 tests, respectively; 2) icv $A\beta_{1-40}$ treatment reduces spatial and recognition memory
31 performance in ghrelin WT mice, but not in ghrelin KO mice since memory performance is
32 already impaired; 3) ip acyl ghrelin treatment recovers memory deficits in ghrelin KO treated
33 icv with aCSF or $A\beta_{1-40}$ and in ghrelin WT treated icv with $A\beta_{1-40}$, but it does not enhance
34 memory performance in control mice (ghrelin WT mice treated icv with aCSF); 4) ghrelin KO
35 mice treated icv with aCSF or $A\beta_{1-40}$ and ghrelin WT treated icv with $A\beta_{1-40}$ show
36 neuroinflammation, as indicated by an increased number of GFAP- and Iba1-positive cells in

1 the rostral hippocampus; 5) acute $A\beta_{1-40}$ depresses HFS-induced LTP, an effect prevented
2 by acyl ghrelin.

3 These findings indicate that the genetic deletion of endogenous ghrelin influences memory
4 performance in a manner similar to $A\beta_{1-40}$ icv injection and that the administration of
5 exogenous acyl ghrelin prevented the decrease in NOR and Y-maze spatial memory in both
6 $A\beta_{1-40}$ -treated mice and in mice lacking ghrelin. The combination of $A\beta_{1-40}$ administration to
7 ghrelin KO mice did not worsen spatial and recognition memory performance beyond $A\beta_{1-40}$
8 administration alone. This is likely to represent a floor effect since ghrelin KO mice were
9 already performing at 50% novel object exploration, where 50% represents no ability to
10 discriminate between novel and familiar objects. Moreover, the equipotent effect of ghrelin
11 deletion and $A\beta_{1-40}$ on neuroinflammation and the ability of acyl ghrelin to prevent $A\beta_{1-40}$ -
12 induced hippocampal synaptic plasticity highlight that these two processes are tightly linked
13 to memory performance. It is likely that these mechanisms underlie the observed effects of
14 ghrelin and $A\beta_{1-40}$ on memory performance. The particular ability of ghrelin deletion to
15 dampen memory performance and, conversely, of exogenous acyl ghrelin to restore memory
16 selectively when is it perturbed, strongly suggests a critical role of ghrelin to prevent memory
17 deterioration rather than acting as a memory enhancer. This is supported by the
18 observations that acyl ghrelin did not enhance memory performance in ghrelin WT mice
19 without $A\beta_{1-40}$ administration.

20 Furthermore, based on the proposed detrimental role of soluble $A\beta$ in early AD (36, 37), the
21 reported findings consolidate the therapeutic potential of manipulating ghrelin signaling in the
22 brain to manage early AD (15-17, 38). This is further heralded by the ability of ghrelin to
23 control two key processes that we have previously shown to critically mediate the early
24 memory dysfunction caused by the icv administration of $A\beta$, namely neuroinflammation (39)
25 and synaptic dysfunction (40, 41). It still remains to be determined if ghrelin might also affect
26 classical pathological features of late phases of AD such as the formation of amyloid plaques
27 and the aggregation of phosphorylated tau since these two features are not recapitulated in
28 the $A\beta_{1-40}$ icv injection model (36, 37), which mostly mimics early AD, as validated in
29 numerous studies (24, 36, 39, 42, 43).

30
31 The spatial Y maze memory test is highly validated and depends on hippocampal function,
32 whereas recognition memory is largely perirhinal-dependent but with a hippocampal
33 component (44-46). Our studies and the work by Diano and colleagues (14) supports a role
34 for ghrelin in the hippocampus in object recognition, however the role of ghrelin in the
35 perirhinal cortex, a key site for object recognition (47), needs to be addressed. We show for
36 the first time that spatial memory is also dependent on endogenous ghrelin production, as

1 ghrelin KO mice showed deficits in Y-maze (spatial memory) performance that could be
2 reversed with acyl ghrelin treatment. These results are consistent with data obtained from
3 GHSR KO mice or GHSR antagonism in the hippocampus, showing that ghrelin signaling
4 requires the GHSR in the hippocampus to promote spatial memory performance (48, 49). It
5 should be noted however, that GHSR deficient rats showed a deficit in radial arm maze food
6 motivated task but not in the water maze (50), suggesting that ghrelin may control context-
7 dependent spatial memory via GHSR signaling (5), which are highly expressed in the
8 hippocampus, particularly the rostral dentate gyrus (3, 19, 51). Considering the important role
9 of ghrelin and GHSR signaling in conveying energy deficit, it is likely that ghrelin/GHSR
10 signaling in the hippocampus enhances spatial learning to promote re-feeding and
11 restoration of energy balance (52, 53). However, this ghrelin/GHSR signaling may operate
12 differently in different brain regions, since contextual fear memory is also dependent on
13 GHSR (5), but is independent of energy balance (54).

14 $A\beta_{1-40}$ treatment reduced both spatial and recognition memory performance in ghrelin WT
15 mice, which was reversed by acyl ghrelin treatment, consistent with previous reports showing
16 the neuroprotective potential of acyl ghrelin in AD (15-17, 20, 38). One possible mechanism
17 through which ghrelin deletion or $A\beta_{1-40}$ affects memory may be neuroinflammation. Indeed,
18 our results show that the elimination of endogenous ghrelin and the exposure to icv $A\beta_{1-40}$
19 increases the number of GFAP- and Iba1-positive cells in the hippocampus, as assessed by
20 unbiased stereological approach, the most reliable and robust methods to accurately estimate
21 cell number within a large area (55). These results are consistent with the known roles of
22 ghrelin in preventing neuroinflammation in models of AD and other neurological disorders
23 (26, 56) and the ability of $A\beta$ to induce neuroinflammation (57). The control of synaptic
24 plasticity, which is the best neurophysiological correlate of memory (58), is another
25 mechanism likely involved in the effects of $A\beta_{1-40}$ and ghrelin on hippocampal-dependent
26 memory. Indeed, the onset of memory impairment in early AD seems to depend on synaptic
27 dysfunction (59) and we now report that the known deleterious effect of $A\beta_{1-40}$ on
28 hippocampal LTP (60) is prevented by the addition of ghrelin. This provides a
29 neurophysiological basis for the ability of ghrelin to prevent $A\beta_{1-40}$ -induced dysfunction.

30 We also showed that deletion of ghrelin significantly impairs olfactory discrimination, which
31 has significant implication in AD, as deficits in olfactory processing are a common feature in
32 early stage AD (29). To the best of our knowledge this is the first demonstration that
33 endogenous ghrelin modulates olfactory function. Our results are consistent with the fact that
34 ghrelin influences olfactory responsiveness to odors, which can be blocked by ghrelin
35 receptor antagonism (61) and ghrelin increases sniffing frequency in mice and humans (30).
36 Together with the high expression of the GHSR in the olfactory bulb (3), these results

1 suggest endogenous ghrelin plays an important role in olfactory discrimination and learning.
2 Nevertheless, neither icv $A\beta_{1-40}$ treatment nor ip acyl ghrelin injections influenced olfactory
3 learning in our experimental conditions. One possibility is that icv $A\beta_{1-40}$ treatment was not
4 sufficiently localized to the regions of the brain processing olfactory information, such as the
5 olfactory bulb and piriform cortex.

6 Given the expression of the GHSR in the olfactory bulb and the strong effects of ghrelin in
7 the olfactory responsiveness and sniffing frequency, the lack of olfactory learning in response
8 to ip acyl ghrelin treatment was initially surprising. This is likely due to the different
9 mechanisms of action of the ghrelin/GHSR signaling to control different memory domains
10 encoded by different brain circuits. In contrast to the control of hippocampal-dependent
11 spatial memory, which may involve neuroinflammation and synaptic plasticity based on our
12 data, the ghrelin/GHSR-mediated control of the consolidation of contextual fear memory
13 instead requires the down-regulation of GHSR in the amygdala (54). The effect of
14 endogenous ghrelin on olfactory memory might involve a different mechanism, such as
15 ghrelin-induced neurogenesis (5, 62), which is known to affect olfactory discrimination (31,
16 32). This would explain the observed lack of effect of ip acyl ghrelin since the generation of
17 functioning new adult born olfactory bulb neurons takes ~28 days (62) and acyl ghrelin would
18 be ineffective following 11 days of treatment (63), when we analyzed olfactory memory. (5,
19 31-34, 62). Future studies are required to address the relationship between ghrelin-induced
20 olfactory bulb neurogenesis and olfactory learning.

21 In this study, we have tested the cognitive effects of $A\beta_{1-40}$ icv treatment in ghrelin WT and
22 KO mice with or without acyl ghrelin treatment. Importantly, ghrelin KO mice lack both des-
23 acyl ghrelin and acyl ghrelin, as both forms are derived from the same proghrelin precursor.
24 Thus, it is possible that the lack of des-acyl ghrelin may also contribute to the memory
25 reported in this study. However, Kang et al, recently showed that acyl ghrelin rather than
26 des-acyl ghrelin is neuroprotective in AD by activating AMPK (16), a result consistent with
27 the neuroprotective actions of acyl ghrelin, and not des-acyl ghrelin, via AMPK signaling in a
28 mouse model of PD (26, 64, 65). The activation of AMPK may drive downstream intracellular
29 mitochondrial pathways to prevent degeneration in AD. Indeed, acyl ghrelin treatment
30 reduces ROS production and prevents mitochondrial membrane depolarization in
31 hippocampal and hypothalamic cells treated with $A\beta$ oligomers (17, 38). These results are
32 similar to the actions of acyl ghrelin in the hypothalamus, substantia nigra and in stroke
33 models (25, 66, 67) suggesting common neuroprotective actions of acyl ghrelin involving the
34 maintenance of mitochondrial homeostasis regardless of the neurological disease.

35 In conclusion, we show that ghrelin deletion impairs spatial and recognition memory as well
36 as olfactory discrimination. Treatment with $A\beta_{1-40}$ icv significantly impairs spatial and

1 recognition memory in ghrelin WT mice but does not further exacerbate the memory deficit in
2 ghrelin KO mice suggesting that the loss of endogenous ghrelin signaling may be associated
3 with $A\beta_{1-40}$ -induced memory deficits. Furthermore, the ability of daily ip injections of acyl
4 ghrelin to restore spatial and recognition memory performance as well as hippocampal
5 synaptic plasticity highlight that enhancing ghrelin secretion may preserve cognitive ability
6 and delay the onset of AD and further support the idea that acyl ghrelin treatment may be
7 therapeutically beneficial to restrict disease progression in early AD.

8 9 **Figure Legends**

10 **Figure 1.** Experimental timeline. Mice were injected icv with $A\beta_{1-40}$ (400 pmol) or vehicle
11 (aCSF) on day 0 and then received ip acyl ghrelin (0.3 mg/kg) at 9 am daily, for 7 days.
12 Novel object recognition (NOR), modified Y-maze, and olfactory discrimination behavioural
13 task were evaluated on days 6, 8 or 17 after icv injection and mice were sacrificed on day 18.

14
15 **Figure 2.** Novel object recognition (NOR). Novel object exploration is the time spent
16 exploring the novel object in the test trial, where 50% represents no difference in exploratory
17 time between the novel and familiar object. $A\beta_{1-40}$ reduces novel object exploration in ghrelin
18 WT mice treated with saline, however this reduction is prevented by daily administration with
19 acyl ghrelin. A main effect of genotype was observed with ghrelin KO mice performing worse
20 than ghrelin WT in NOR. Daily ip injection of acyl ghrelin increased novel object exploration
21 in both ghrelin WT and KO mice (main effect of hormone treatment). In addition, a main
22 effect of peptide treatment (icv $A\beta_{1-40}$ treatment) was also observed indicating that icv $A\beta_{1-40}$
23 treatment worsened recognition memory performance. Significant interactions between
24 hormone treatment and genotype, and between hormone treatment, genotype and peptide
25 treatment were observed. Data are presented as mean \pm SEM, n=10 per group, three-way
26 ANOVA with Tukey's post hoc analysis to identify significant difference between groups. a,
27 significant difference ($p < 0.05$) between aCSF and $A\beta_{1-40}$ treatment. The dotted line indicates
28 50% in novel object recognition, which represents no ability to discriminate between novel
29 and familiar objects (chance).

30
31 **Figure 3.** Modified Y-maze where we quantified the time spent in the novel arm in the
32 second visit to the Y-maze 30 minutes after a previous visit where this arm was closed. $A\beta_{1-40}$
33 reduces the time spent in the novel arm in ghrelin WT mice treated with saline, and this
34 reduction is prevented by daily administration of acyl ghrelin. Daily ip acyl ghrelin treatment
35 increased time spent in the novel arm relative to ip saline injections (main effect of hormone
36 treatment) and ghrelin KO mice performed worse in the Y-maze task compared to ghrelin WT

1 mice (main effect of genotype). A main effect of peptide treatment (icv $A\beta_{1-40}$ treatment) was
2 also observed indicating that icv $A\beta_{1-40}$ treatment worsened spatial memory performance.
3 Significant interactions between hormone treatment and genotype; between genotype and
4 peptide treatment; and between hormone treatment, genotype and peptide treatment were
5 observed. Data are presented as mean \pm SEM, $n=10$ per group, three-way ANOVA with
6 Tukey's post hoc analysis to identify significant difference between groups. a, significant
7 difference ($p<0.05$) between aCSF and $A\beta_{1-40}$ treatment.

8
9 **Figure 4.** Olfactory discrimination was determined by comparing the amount of time mice
10 spent in a chamber with familiar bedding compared to the time spent in an adjoining chamber
11 with non-familiar bedding. The olfactory discrimination index measures the preference for the
12 familiar bedding with 0.5 being equal to no preference, as indicated by the dotted line. We
13 observed a main effect of genotype on olfactory discrimination, but no effect of hormone or
14 peptide treatment, indicating ghrelin KO mice performed worse than WT mice, independent
15 of acyl ghrelin or $A\beta_{1-40}$ treatment. Data are presented as mean \pm SEM, $n=10$ per group,
16 three-way ANOVA with Tukey's post hoc analysis to identify significant difference between
17 groups.

18
19 **Figure 5.** Stereological estimation of the number of GFAP- and Iba1-positive cells in the
20 rostral hippocampus. (A) Ghrelin KO mice exhibited a significantly greater number of GFAP-
21 positive cells in the rostral hippocampus compared to ghrelin WT mice, both groups treated
22 icv with aCSF. $A\beta_{1-40}$ icv treatment increased the number of GFAP-positive cells in ghrelin
23 WT but not in ghrelin KO mice. (B) Ghrelin KO mice exhibited a significantly greater number
24 of Iba1-positive cells in the rostral hippocampus compared to ghrelin WT mice, both groups
25 treated icv with aCSF. $A\beta_{1-40}$ icv treatment increased the number of GFAP-positive cells in
26 ghrelin WT but not in ghrelin KO mice. Data are presented as mean \pm SEM, $n=10$ per
27 group, two-way ANOVA with Newman-Keuls post hoc analysis to identify significant
28 difference between groups. a, significant difference ($p<0.05$) between groups, as indicated by
29 the horizontal lines.

30
31 **Figure 6.** Hippocampal LTP. Bath application of $A\beta_{1-40}$ (either 200 or 500 nM) prevents LTP
32 induced by HFS (A-B). Acyl ghrelin increases HFS-induced LTP as measured by the percent
33 increase in fEPSPs before and 60 minutes after HFS in the absence and presence of acyl
34 ghrelin (1 nM or 1 μ M; C-D). Co-application of acyl ghrelin with $A\beta_{1-40}$ prevents the $A\beta_{1-40}$ -
35 induced suppression of hippocampal LTP. Data are presented as mean \pm SEM, $n=4$ per
36 group, one-way ANOVA with Newman-Keuls post hoc analysis to identify significant

1 difference between groups. a, significantly different ($p < 0.05$) from control group; b,
2 significantly different ($p < 0.05$) from ghrelin 1nM + $A\beta_{1-40}$ 200 nM.

3
4

5 REFERENCES

- 6 1. Muller TD, Nogueiras R, Andermann ML, Andrews ZB, Anker SD, Argente J,
7 Batterham RL, Benoit SC, Bowers CY, Broglio F, Casanueva FF, D'Alessio D, Depoortere I,
8 Geliebter A, Ghigo E, Cole PA, Cowley M, Cummings DE, Dagher A, Diano S, Dickson SL,
9 Dieguez C, Granata R, Grill HJ, Grove K, Habegger KM, Heppner K, Heiman ML, Holsen L,
10 Holst B, Inui A, Jansson JO, Kirchner H, Korbonits M, Laferrere B, LeRoux CW, Lopez M,
11 Morin S, Nakazato M, Nass R, Perez-Tilve D, Pfluger PT, Schwartz TW, Seeley RJ,
12 Sleeman M, Sun Y, Sussel L, Tong J, Thorner MO, van der Lely AJ, van der Ploeg LH,
13 Zigman JM, Kojima M, Kangawa K, Smith RG, Horvath T, Tschop MH. Ghrelin. *Mol Metab.*
14 2015; **4**(6): 437-60.
- 15 2. Zigman JM, Bouret SG, Andrews ZB. Correction to 'Obesity Impairs the Action of the
16 Neuroendocrine Ghrelin System': [Trends in Endocrinology and Metabolism, 27 (2016) 54-
17 63]. *Trends Endocrinol Metab.* 2016; **27**(5): 348.
- 18 3. Mani BK, Walker AK, Lopez Soto EJ, Raingo J, Lee CE, Perello M, Andrews ZB,
19 Zigman JM. Neuroanatomical characterization of a growth hormone secretagogue receptor-
20 green fluorescent protein reporter mouse. *J Comp Neurol.* 2014; **522**(16): 3644-66.
- 21 4. Bayliss JA, Lemus MB, Stark R, Santos VV, Thompson A, Rees DJ, Galic S,
22 Elsworth JD, Kemp BE, Davies JS, Andrews ZB. Ghrelin-AMPK Signaling Mediates the
23 Neuroprotective Effects of Calorie Restriction in Parkinson's Disease. *J Neurosci.* 2016;
24 **36**(10): 3049-63.
- 25 5. Hornsby AK, Redhead YT, Rees DJ, Ratcliff MS, Reichenbach A, Wells T, Francis L,
26 Amstalden K, Andrews ZB, Davies JS. Short-term calorie restriction enhances adult
27 hippocampal neurogenesis and remote fear memory in a Ghrelin-dependent manner.
28 *Psychoneuroendocrinology.* 2015; **63**:198-207.
- 29 6. McFarlane MR, Brown MS, Goldstein JL, Zhao TJ. Induced ablation of ghrelin cells in
30 adult mice does not decrease food intake, body weight, or response to high-fat diet. *Cell*
31 *Metab.* 2014; **20**(1): 54-60.
- 32 7. Zhao TJ, Liang G, Li RL, Xie X, Sleeman MW, Murphy AJ, Valenzuela DM,
33 Yancopoulos GD, Goldstein JL, Brown MS. Ghrelin O-acyltransferase (GOAT) is essential

- 1 for growth hormone-mediated survival of calorie-restricted mice. *Proc Natl Acad Sci U S A*.
2 2010; **107**(16): 7467-72.
- 3 8. Lutter M, Sakata I, Osborne-Lawrence S, Rovinsky SA, Anderson JG, Jung S,
4 Birnbaum S, Yanagisawa M, Elmquist JK, Nestler EJ, Zigman JM. The orexigenic hormone
5 ghrelin defends against depressive symptoms of chronic stress. *Nat Neurosci*. 2008; **11**(7):
6 752-3.
- 7 9. Briggs DI, Andrews ZB. Metabolic status regulates ghrelin function on energy
8 homeostasis. *Neuroendocrinology*. 2011; **93**(1): 48-57.
- 9 10. Halagappa VK, Guo Z, Pearson M, Matsuoka Y, Cutler RG, Laferla FM, Mattson MP.
10 Intermittent fasting and caloric restriction ameliorate age-related behavioral deficits in the
11 triple-transgenic mouse model of Alzheimer's disease. *Neurobiol Dis*. 2007; **26**(1): 212-20.
- 12 11. Wang J, Ho L, Qin W, Rocher AB, Seror I, Humala N, Maniar K, Dolios G, Wang R,
13 Hof PR, Pasinetti GM. Caloric restriction attenuates beta-amyloid neuropathology in a
14 mouse model of Alzheimer's disease. *FASEB J*. 2005; **19**(6): 659-61.
- 15 12. Theodoropoulou A, Metallinos IC, Psyrogiannis A, Vagenakis GA, Kyriazopoulou V.
16 Ghrelin and leptin secretion in patients with moderate Alzheimer's disease. *J Nutr Health*
17 *Aging*. 2012; **16**(5): 472-7.
- 18 13. Shibata N, Ohnuma T, Kuerban B, Komatsu M, Arai H. Genetic association between
19 ghrelin polymorphisms and Alzheimer's disease in a Japanese population. *Dement Geriatr*
20 *Cogn Disord*. 2011; **32**(3): 178-81.
- 21 14. Diano S, Farr SA, Benoit SC, McNay EC, da Silva I, Horvath B, Gaskin FS, Nonaka
22 N, Jaeger LB, Banks WA, Morley JE, Pinto S, Sherwin RS, Xu L, Yamada KA, Sleeman MW,
23 Tschop MH, Horvath TL. Ghrelin controls hippocampal spine synapse density and memory
24 performance. *Nature Neuroscience*. 2006; **9**(3): 381-8.
- 25 15. Moon M, Choi JG, Nam DW, Hong HS, Choi YJ, Oh MS, Mook-Jung I. Ghrelin
26 ameliorates cognitive dysfunction and neurodegeneration in intrahippocampal amyloid-
27 beta1-42 oligomer-injected mice. *J Alzheimers Dis*. 2011; **23**(1): 147-59.
- 28 16. Kang S, Moon NR, Kim da S, Kim SH, Park S. Central acylated ghrelin improves
29 memory function and hippocampal AMPK activation and partly reverses the impairment of
30 energy and glucose metabolism in rats infused with beta-amyloid. *Peptides*. 2015; **71**:84-93.
- 31 17. Martins I, Gomes S, Costa RO, Otvos L, Oliveira CR, Resende R, Pereira CM. Leptin
32 and ghrelin prevent hippocampal dysfunction induced by Abeta oligomers. *Neuroscience*.
33 2013; **241**:41-51.

- 1 18. Moon M, Cha MY, Mook-Jung I. Impaired hippocampal neurogenesis and its
2 enhancement with ghrelin in 5XFAD mice. *J Alzheimers Dis.* 2014; **41**(1): 233-41.
- 3 19. Kent BA, Beynon AL, Hornsby AK, Bekinschtein P, Bussey TJ, Davies JS, Saksida
4 LM. The orexigenic hormone acyl-ghrelin increases adult hippocampal neurogenesis and
5 enhances pattern separation. *Psychoneuroendocrinology.* 2015; **51**:431-9.
- 6 20. Dhurandhar EJ, Allison DB, van Groen T, Kadish I. Hunger in the absence of caloric
7 restriction improves cognition and attenuates Alzheimer's disease pathology in a mouse
8 model. *PLoS One.* 2013; **8**(4): e60437.
- 9 21. Kunath N, van Groen T, Allison DB, Kumar A, Dozier-Sharpe M, Kadish I. Ghrelin
10 agonist does not foster insulin resistance but improves cognition in an Alzheimer's disease
11 mouse model. *Scientific reports.* 2015; **5**:11452.
- 12 22. Wortley KE, Anderson KD, Garcia K, Murray JD, Malinova L, Liu R, Moncrieffe M,
13 Thabet K, Cox HJ, Yancopoulos GD, Wiegand SJ, Sleeman MW. Genetic deletion of ghrelin
14 does not decrease food intake but influences metabolic fuel preference. *Proc Natl Acad Sci*
15 *U S A.* 2004; **101**(21): 8227-32.
- 16 23. Wortley KE, del Rincon JP, Murray JD, Garcia K, Iida K, Thorner MO, Sleeman MW.
17 Absence of ghrelin protects against early-onset obesity. *J Clin Invest.* 2005; **115**(12): 3573-8.
- 18 24. Prediger RDS, Franco JL, Pandolfo P, Medeiros R, Duarte FS, Di Giunta G,
19 Figueiredo CP, Farina M, Calixto JB, Takahashi RN, Dafre AL. Differential susceptibility
20 following beta-amyloid peptide-(1-40) administration in C57BL/6 and Swiss albino mice:
21 Evidence for a dissociation between cognitive deficits and the glutathione system response.
22 *Behavioural Brain Research.* 2007; **177**(2): 205-13.
- 23 25. Andrews ZB, Erion D, Beiler R, Liu ZW, Abizaid A, Zigman J, Elsworth JD, Savitt JM,
24 DiMarchi R, Tschoep M, Roth RH, Gao XB, Horvath TL. Ghrelin promotes and protects
25 nigrostriatal dopamine function via a UCP2-dependent mitochondrial mechanism. *J*
26 *Neurosci.* 2009; **29**(45): 14057-65.
- 27 26. Bayliss JA, Lemus M, Santos VV, Deo M, Elsworth J, Andrews ZB. Acylated but not
28 des-acyl ghrelin is neuroprotective in an MPTP mouse model of Parkinson's Disease. *J*
29 *Neurochem.* 2016.
- 30 27. Kaster MP, Machado NJ, Silva HB, Nunes A, Ardais AP, Santana M, Baqi Y, Muller
31 CE, Rodrigues ALS, Porciuncula LO, Chen JF, Tome AR, Agostinho P, Canas PM, Cunha
32 RA. Caffeine acts through neuronal adenosine A(2A) receptors to prevent mood and
33 memory dysfunction triggered by chronic stress. *Proceedings of the National Academy of*
34 *Sciences of the United States of America.* 2015; **112**(25): 7833-8.

- 1 28. Anderson WW, Collingridge GL. The LTP Program: a data acquisition program for
2 on-line analysis of long-term potentiation and other synaptic events. *J Neurosci Methods*.
3 2001; **108**(1): 71-83.
- 4 29. Attems J, Walker L, Jellinger KA. Olfactory bulb involvement in neurodegenerative
5 diseases. *Acta Neuropathol*. 2014; **127**(4): 459-75.
- 6 30. Tong J, Mannea E, Aime P, Pfluger PT, Yi CX, Castaneda TR, Davis HW, Ren X,
7 Pixley S, Benoit S, Julliard K, Woods SC, Horvath TL, Sleeman MM, D'Alessio D, Obici S,
8 Frank R, Tschop MH. Ghrelin enhances olfactory sensitivity and exploratory sniffing in
9 rodents and humans. *The Journal of neuroscience : the official journal of the Society for*
10 *Neuroscience*. 2011; **31**(15): 5841-6.
- 11 31. Sultan S, Mandairon N, Kermen F, Garcia S, Sacquet J, Didier A. Learning-
12 dependent neurogenesis in the olfactory bulb determines long-term olfactory memory.
13 *FASEB J*. 2010; **24**(7): 2355-63.
- 14 32. Moreno MM, Linster C, Escanilla O, Sacquet J, Didier A, Mandairon N. Olfactory
15 perceptual learning requires adult neurogenesis. *Proc Natl Acad Sci U S A*. 2009; **106**(42):
16 17980-5.
- 17 33. Enwere E, Shingo T, Gregg C, Fujikawa H, Ohta S, Weiss S. Aging results in
18 reduced epidermal growth factor receptor signaling, diminished olfactory neurogenesis, and
19 deficits in fine olfactory discrimination. *J Neurosci*. 2004; **24**(38): 8354-65.
- 20 34. Alonso M, Viollet C, Gabellec MM, Meas-Yedid V, Olivo-Marin JC, Lledo PM.
21 Olfactory discrimination learning increases the survival of adult-born neurons in the olfactory
22 bulb. *J Neurosci*. 2006; **26**(41): 10508-13.
- 23 35. Moon M, Kim S, Hwang L, Park S. Ghrelin regulates hippocampal neurogenesis in
24 adult mice. *Endocr J*. 2009; **56**(3): 525-31.
- 25 36. Takeda S, Sato N, Niisato K, Takeuchi D, Kurinami H, Shinohara M, Rakugi H, Kano
26 M, Morishita R. Validation of A beta 1-40 administration into mouse cerebroventricles as an
27 animal model for Alzheimer disease. *Brain Res*. 2009; **1280**:137-47.
- 28 37. Van Dam D, De Deyn PP. The Role of Rodent Models in the Drug Discovery Pipeline
29 for Dementia. *Neuromethods*. 2011; **48**:35-49.
- 30 38. Gomes S, Martins I, Fonseca AC, Oliveira CR, Resende R, Pereira CM. Protective
31 effect of leptin and ghrelin against toxicity induced by amyloid-beta oligomers in a
32 hypothalamic cell line. *J Neuroendocrinol*. 2014; **26**(3): 176-85.


- 1 39. Medeiros R, Prediger RD, Passos GF, Pandolfo P, Duarte FS, Franco JL, Dafre AL,
2 Di Giunta G, Figueiredo CP, Takahashi RN, Campos MM, Calixto JB. Connecting TNF-alpha
3 signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: relevance
4 for the behavioral and synaptic deficits induced by amyloid beta protein. *J Neurosci.* 2007;
5 **27**(20): 5394-404.
- 6 40. Canas PM, Porciuncula LO, Cunha GMA, Silva CG, Machado NJ, Oliveira JMA,
7 Oliveira CR, Cunha RA. Adenosine A(2A) Receptor Blockade Prevents Synaptotoxicity and
8 Memory Dysfunction Caused by beta-Amyloid Peptides via p38 Mitogen-Activated Protein
9 Kinase Pathway. *Journal of Neuroscience.* 2009; **29**(47): 14741-51.
- 10 41. Canas PM, Simoes AP, Rodrigues RJ, Cunha RA. Predominant loss of glutamatergic
11 terminal markers in a beta-amyloid peptide model of Alzheimer's disease.
12 *Neuropharmacology.* 2014; **76**51-6.
- 13 42. Mattson MR. Molecular and cellular pathways towards and away from Alzheimer's
14 disease. *Res Per Alz.* 2006371-5.
- 15 43. dos Santos VV, Santos DB, Lach G, Rodrigues ALS, Farina M, De Lima TCM,
16 Prediger RD. Neuropeptide Y (NPY) prevents depressive-like behavior, spatial memory
17 deficits and oxidative stress following amyloid-beta (A beta(1-40)) administration in mice.
18 *Behavioural Brain Research.* 2013; **244**107-15.
- 19 44. Yi JH, Park HJ, Kim BC, Kim DH, Ryu JH. Evidences of the role of the rodent
20 hippocampus in the non-spatial recognition memory. *Behav Brain Res.* 2016; **297**141-9.
- 21 45. Vann SD, Albasser MM. Hippocampus and neocortex: recognition and spatial
22 memory. *Current opinion in neurobiology.* 2011; **21**(3): 440-5.
- 23 46. Broadbent NJ, Squire LR, Clark RE. Spatial memory, recognition memory, and the
24 hippocampus. *Proc Natl Acad Sci U S A.* 2004; **101**(40): 14515-20.
- 25 47. Brown MW, Warburton EC, Aggleton JP. Recognition Memory: Material, Processes,
26 and Substrates. *Hippocampus.* 2010; **20**(11): 1228-44.
- 27 48. Beheshti S, Shahrokhi S. Blocking the ghrelin receptor type 1a in the rat brain
28 impairs memory encoding. *Neuropeptides.* 2015; **52**97-102.
- 29 49. Davis JF, Choi DL, Clegg DJ, Benoit SC. Signaling through the ghrelin receptor
30 modulates hippocampal function and meal anticipation in mice. *Physiol Behav.* 2011; **103**(1):
31 39-43.

- 1 50. Cahill SP, Hatchard T, Abizaid A, Holahan MR. An examination of early neural and
2 cognitive alterations in hippocampal-spatial function of ghrelin receptor-deficient rats. *Behav*
3 *Brain Res.* 2014; **264**:105-15.
- 4 51. Zigman JM, Jones JE, Lee CE, Saper CB, Elmquist JK. Expression of ghrelin
5 receptor mRNA in the rat and the mouse brain. *J Comp Neurol.* 2006; **494**(3): 528-48.
- 6 52. Hsu TM, Hahn JD, Konanur VR, Noble EE, Suarez AN, Thai J, Nakamoto EM,
7 Kanoski SE. Hippocampus ghrelin signaling mediates appetite through lateral hypothalamic
8 orexin pathways. *eLife.* 2015; **4**.
- 9 53. Kanoski SE, Grill HJ. Hippocampus Contributions to Food Intake Control: Mnemonic,
10 Neuroanatomical, and Endocrine Mechanisms. *Biol Psychiatry.* 2015.
- 11 54. Harmatz ES, Stone S, Lim SH, Lee G, McGrath A, Gisabella B, Peng X, Kosoy E,
12 Yao J, Lui E, Machado NJ, Weiner VS, Slocum W, Cunha RA, Goosens KA. Central Ghrelin
13 Resistance Permits the Overconsolidation of Fear Memory. *Biological Psychiatry.* 2016.
- 14 55. Schmitz C, Hof PR. Design-based stereology in neuroscience. *Neuroscience.* 2005;
15 **130**(4): 813-31.
- 16 56. Dixit VD, Schaffer EM, Pyle RS, Collins GD, Sakthivel SK, Palaniappan R, Lillard JW,
17 Jr., Taub DD. Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine
18 expression by human monocytes and T cells. *J Clin Invest.* 2004; **114**(1): 57-66.
- 19 57. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL,
20 Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, Herrup K, Frautschy SA, Finsen B,
21 Brown GC, Verkhratsky A, Yamanaka K, Koistinaho J, Latz E, Halle A, Petzold GC, Town T,
22 Morgan D, Shinohara ML, Perry VH, Holmes C, Bazan NG, Brooks DJ, Hunot S, Joseph B,
23 Deigendesch N, Garaschuk O, Boddeke E, Dinarello CA, Breitner JC, Cole GM, Golenbock
24 DT, Kummer MP. Neuroinflammation in Alzheimer's disease. *The Lancet Neurology.* 2015;
25 **14**(4): 388-405.
- 26 58. Martin SJ, Grimwood PD, Morris RGM. Synaptic plasticity and memory: An
27 evaluation of the hypothesis. *Annual Review of Neuroscience.* 2000; **23**:649-711.
- 28 59. Selkoe DJ. Alzheimer's disease is a synaptic failure. *Science.* 2002; **298**(5594): 789-
29 91.
- 30 60. Ondrejcek T, Klyubin I, Hu NW, Barry AE, Cullen WK, Rowan MJ. Alzheimer's
31 Disease Amyloid beta-Protein and Synaptic Function. *Neuromol Med.* 2010; **12**(1): 13-26.
- 32 61. Loch D, Breer H, Strotmann J. Endocrine Modulation of Olfactory Responsiveness:
33 Effects of the Orexigenic Hormone Ghrelin. *Chemical senses.* 2015; **40**(7): 469-79.

- 1 62. Li E, Kim Y, Kim S, Sato T, Kojima M, Park S. Ghrelin stimulates proliferation,
2 migration and differentiation of neural progenitors from the subventricular zone in the adult
3 mice. *Exp Neurol*. 2014; **252**:75-84.
- 4 63. Zhao C, Deng W, Gage FH. Mechanisms and functional implications of adult
5 neurogenesis. *Cell*. 2008; **132**(4): 645-60.
- 6 64. Bayliss JA, Andrews ZB. Ghrelin is neuroprotective in Parkinson's disease: molecular
7 mechanisms of metabolic neuroprotection. *Ther Adv Endocrinol Metab*. 2013; **4**(1): 25-36.
- 8 65. Bayliss JA, Lemus M, Santos VV, Deo M, Elsworth JD, Andrews ZB. Acylated but not
9 des-acyl ghrelin is neuroprotective in an MPTP mouse model of Parkinson's disease. *J*
10 *Neurochem*. 2016; **137**(3): 460-71.
- 11 66. Andrews ZB, Liu ZW, Wallingford N, Erion DM, Borok E, Friedman JM, Tschop MH,
12 Shanabrough M, Cline G, Shulman GI, Coppola A, Gao XB, Horvath TL, Diano S. UCP2
13 mediates ghrelin's action on NPY/AgRP neurons by lowering free radicals. *Nature*. 2008;
14 **454**(7206): 846-51.
- 15 67. Chung H, Kim E, Lee DH, Seo S, Ju S, Lee D, Kim H, Park S. Ghrelin inhibits
16 apoptosis in hypothalamic neuronal cells during oxygen-glucose deprivation. *Endocrinology*.
17 2007; **148**(1): 148-59.


18

icv $A\beta_{1-40}$ (400 pmol)
or aCSF




jne_12476_f1.tiff


Author Manuscript




jne_12476_f2.tiff



jne_12476_f3.tiff









jne_12476_f4.tiff



jne_12476_f5.tiff

Author Manuscript



jne_12476_f6.tiff